ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (ChariotMS)

  • STATUS
    Recruiting
  • End date
    Jul 4, 2024
  • participants needed
    200
  • sponsor
    Queen Mary University of London
Send
Updated on 30 June 2022
See if I qualify

Summary

MS is a chronic inflammatory and degenerative disease of the central nervous system (CNS) affecting more than 120,000 people in the UK.and 2.5 million people worldwide.

Without disease modifying treatment (DMT),the majority of people with MS (pwMS) will develop significant disability within 10 years of onset, and 50% will require wheelchair assistance within 20 years. convenient, highly effective and CNS penetrant DMT for patients with relapsing multiple sclerosis (pwRMS) administered in short (8-10 days/year over 2 years) treatment courses.

It effectively depletes B cells, particularly Memory B cells, a likely key mechanism of disease control in MS. Cladribine is the investigational product in this study as it not currently used to treat patients with an EDSS of 6.5 - 8.5. This is a multi-centre, randomised double-blind placebo-controlled phase IIb to test cladribine tablets (MAVENCLAD®) (3.5mg/kg over 24 months) for safety, efficacy, and cost effectiveness, and to advance mechanistic understanding of its action in people with advanced MS (pwAMS).

Details
Condition Advanced Multiple Sclerosis, Progressive Multiple Sclerosis
Treatment Placebo, Cladribine (MAVENCLAD®)
Clinical Study IdentifierNCT04695080
SponsorQueen Mary University of London
Last Modified on30 June 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

pwAMS aged 18+ years with an EDSS of 6.5-8.5 (inclusive)
History of bowel cancer screening for men and women and cervical and breast cancer screening for women as per NHS recommended guidelines. <https://www.nhs.uk/conditions/nhs-screening/>
Ability to complete the 9HPT with either upper limb within 180 seconds. The average score of both attempts for each hand should be used to assess eligibility
Confirmation of MS diagnosis according to the McDonald Criteria (2017) Thompson et al. 2018)
In the judgement of the investigator, evidence of deterioration of upper limb function during the 2 years running up to the screening date

Exclusion Criteria

Participants with known hypersensitivity to Cladribine of any grade (as per CTCAE grading system) should be excluded
Any uncontrolled diabetes, arterial hypertension and hypercholesterolaemia as determined by PI or delegated sub-investigator
A history of stroke, deep vein or sinus venous thrombosis and/or myocardial infarction
Moderate to severe renal impairment (creatinine clearance <60 ml/min)
Moderate to severe hepatic impairment (Child-Pugh score >6)
Significant comorbidity, e.g. cardiac failure, renal failure, malignancy, or other health condition that in the view of the PI or delegated sub-investigator precludes participation
Pregnancy including planning to father a child or breastfeeding
Body weight less <40kg
Unwillingness to use effective contraception throughout the trial period until at least six months after the last administration of IMP. This is not applicable for post-menopausal women
Acute infection
Infection with Human Immunodeficiency Virus 1 and/or 2
Active chronic infection (Syphilis, Tuberculosis, Hepatitis)
Precancerous condition or previous diagnosis of cancer
Total lymphocyte count <1.0109/mL
Seronegativity for varicella zoster IgG, rubella, measles, mumps. Potential participants who fall in this category may undergo vaccination and can be screened (again) once full course has been completed
Relapse within six months before screening
Inability to complete an MRI (contraindications for MRI, including but not limited to, MRI non- compatible pacemaker, cochlear implants, intracranial vascular clips, surgery within 6 weeks of entry in the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, severe anxiety or claustrophobia etc.) or contraindication to Gd administration
Treatment with steroids due to MS relapse/progression within three months of screening
pwAMS who fall in this category may undergo a further screening visit once the
three months' window has expired and may be included if no steroid treatment
has been administered in the intervening period
Treatment with any interferon-beta, glatiramer acetate, teriflunomide or dimethyl-fumarate within three months before screening
Treatment with natalizumab, fingolimod, siponimod, ponesimod, ozanimod (or other Sphingosine-1-phosphate receptor modulators) within three months of screening
Treatment with azathioprine, methotrexate, or cyclosporine within six months before screening
pwAMS treated with teriflunomide will need to undergo accelerated elimination of the compound before being considered (Research and Case Medical Research 2019)
Treatment with haematopoietic stem cell transplantation (HSCT), mitoxantrone, cyclophosphamide, cladribine, alemtuzumab or another B cell depleting compound, such as rituximab, ocrelizumab, ublitiuximab, ofatumumab, or biosimilars, unless the participant concerned has a memory B cell level of ≥20% of the CD19+ population in the peripheral blood. Such a level would normally not be expected earlier than a minimum of six months after the last drug administration. Participants who underwent such treatment will therefore have to be tested for their CD19+/CD27+ memory B cell level at screening
Treatment with fampridine: If they are already on treatment for at least six months, participants should continue throughout the trial. However, starting continuous fampridine treatment after signing the consent sheet will lead to exclusion from treatment with IMP/placebo
Concurrent participation or previous participation within the last 6 months in another clinical trial of an IMP or medical device
Unable to swallow tablets
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note